HANGZHOU TIGERMED CONSULTING CO., LTD Hangzhou Tigermed Consulting Co., Ltd Stock
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.05 CNY | +0.25% |
|
+5.98% | +3.78% |
| Apr. 25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
| Apr. 25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
| Sales 2024 * | 7.94B 1.1B | Sales 2025 * | 9.33B 1.29B | Capitalization | 45.98B 6.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.05B 283M | Net income 2025 * | 2.53B 349M | EV / Sales 2024 * | 5.03 x |
| Net cash position 2024 * | 6B 829M | Net cash position 2025 * | 8.35B 1.15B | EV / Sales 2025 * | 4.03 x |
| P/E ratio 2024 * |
24.2
x | P/E ratio 2025 * |
19.6
x | Employees | - |
| Yield 2024 * |
0.88% | Yield 2025 * |
1.1% | Free-Float | 69.68% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.87% | ||
| 1 week | +5.72% | ||
| Current month | +5.53% | ||
| 1 month | -7.84% | ||
| 3 months | +28.58% | ||
| 6 months | -1.23% | ||
| Current year | +3.53% |
1 week
52.30
57.20
1 month
52.3063.36
Current year
36.1263.36
1 year
36.1274.85
3 years
36.12209.41
5 years
36.12209.41
10 years
9.47209.41
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Hao Wu
PSD | President | 56 | 19-12-31 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Bing Hui Zhang
CHM | Chairman | 61 | 20-04-27 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 57.05 | +0.25% | 9 795 335 |
| 24-06-06 | 56.91 | +2.87% | 9,368,382 |
| 24-06-05 | 55.32 | -0.32% | 5,851,840 |
| 24-06-04 | 55.5 | +3.54% | 9,540,997 |
| 24-06-03 | 53.6 | -0.61% | 8,610,114 |
End-of-day quote Shenzhen S.E., June 05, 2024
More quotes
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows:
- provision of clinical trial services and related technological services (51.8%);
- provision of clinical research consulting services (48.2%).
China accounts for 46% of sales.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
56.91
CNY
Average target price
72.82
CNY
Spread / Average Target
+27.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.53% | 6.35B | |
| +55.55% | 59.28B | |
| +43.17% | 40.94B | |
| -4.71% | 40.17B | |
| -5.56% | 28.69B | |
| +13.76% | 26.63B | |
| -22.00% | 18.89B | |
| +31.50% | 12.46B | |
| +2.16% | 12.42B | |
| +25.70% | 12.26B |
- Stock Market
- Equities
- 300347 Stock
